Multiple targeting by the antitumor drug tamoxifen: a structure-activity study

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Tamoxifen is a primary endocrine therapy for estrogen receptor-positive breast cancer.
• Its therapeutic effects are attributed to estrogen receptor (ER) binding and interactions with other cellular targets.
• These interactions include binding to the antiestrogen binding site (AEBS) and inhibition of protein kinase C (PKC), calmodulin (CaM)-dependent enzymes, and Acyl CoenzymeA: Cholesterol Acyl Transferase (ACAT).

Purpose of the Study:

• To review the current understanding of tamoxifen's structural features responsible for its multiple target interactions.
• To explore how these interactions contribute to both genomic and non-genomic effects of tamoxifen.
• To provide insights for the rational design of novel selective ligands targeting ER, AEBS, PKC, CaM, or ACAT.

Main Methods:

• Literature review of studies on tamoxifen's molecular interactions.
• Analysis of structure-activity relationships for tamoxifen and its targets.
• Comparative analysis of binding affinities and inhibitory efficiencies.

Main Results:

• Tamoxifen exhibits high affinity for the estrogen receptor (ER).
• It also binds with comparable affinity to the microsomal antiestrogen binding site (AEBS).
• Tamoxifen inhibits protein kinase C (PKC), calmodulin (CaM)-dependent enzymes, and Acyl CoenzymeA: Cholesterol Acyl Transferase (ACAT) with micromolar efficiency.

Conclusions:

• Tamoxifen's multiple targeting capabilities, including ER, AEBS, PKC, CaM, and ACAT, likely mediate its diverse biological effects.
• Understanding the structural basis of these interactions is crucial for drug design.
• This knowledge can guide the development of more selective modulators for specific therapeutic applications in breast cancer and beyond.